Recordati.
Italian pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 20
What's happening
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Ionis Pharmaceuticals licensed Zilganersen to Recordati, which is now undergoing international regulatory filings and FDA review.Some support1 report
-
Recordati held its Board of Directors meeting in Milan on July 30, 2025, as a licensing agreement strengthened its SPC business in Europe.Some support2 reports
-
Merck announced the acquisition of Verona, while Recordati reported royalty earnings and Ligand Pharmaceuticals updated its CEO.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Recordati this week
News at the entities that move Recordati most-
Amarin (United Kingdom) OperationalTrump's pledge to unleash American oil and gas is linked to US stocks and software companies Amarin and Salesforce.Moves Recordati
-
Ionis Pharmaceuticals TransactionalGSK and Ionis Pharmaceuticals co-developed the bepirovirsen drug for hepatitis B.Moves Recordati
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Recordati
-
board of directors StructuralThe Coldwater Area Chamber of Commerce is seeking nominations for its leadership body.Moves Recordati
-
Moderna OperationalAnalyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Moves Recordati
-
Europe Shared contextThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Recordati
Connections
The 8 strongest of 20, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Amarin (United Kingdom) Operational
Recordati and Amarin established a partnership for the exclusive licensing and commercialization of Vazkepa in the EU.
-
Ionis Pharmaceuticals Transactional
Ionis licensed Zilganersen to Recordati.
-
FDA Structural
Recordati operates under the formal regulatory oversight of the FDA for market access in the United States.
-
board of directors Structural
Recordati operates under the formal governance structure of its board of directors, which approves interim financial statements.
-
Moderna Operational
The companies are engaged in a strategic collaboration focused on shared research and commercialization goals.
-
Laura Broutier Transactional
Recordati provides a €250,000 research grant to support Laura Broutier's DISARMS project.
-
Europe Shared context
Recordati conducts licensing and commercialization activities within the European market.
-
Milan Shared context
Recordati conducts its corporate activities, such as board meetings and publishing statements, within Milan.
History
Events by the month they beganSeptember 2026
1 eventJuly 2026
1 eventJune 2026
3 events- Ionis Pharmaceuticals licensed Zilganersen to Recordati, which is now undergoing international regulatory filings and FDA review.
- Recordati held its Board of Directors meeting in Milan on July 30, 2025, as a licensing agreement strengthened its SPC business in Europe.
- Merck announced the acquisition of Verona, while Recordati reported royalty earnings and Ligand Pharmaceuticals updated its CEO.